Pulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms

NCT07834918 | Not Yet Recruiting

• 1 other identifier: MPN-PH-RVD-Assiut-2026
• Study Type: observational
• Target: 145
• Locations: 0 countries
• Sites: N/A

Brief Summary

This cross-sectional study aims to determine the prevalence of pulmonary hypertension and right ventricular dysfunction in patients with myeloproliferative neoplasms and to identify associated clinical and hematologic factors.

Conditions

Right Ventricular Dysfunction; Myeloproliferative Neoplasm; Pulmonary Hypertension

Keywords

Assiut; Echocardiography; Right ventricular dysfunction; Myeloproliferative neoplasm; Pulmonary hypertension

Outcome Measures

Primary Outcomes (1)

• Prevalence of Pulmonary Hypertension in MPN Patients

  PASP measured by echocardiography using TR velocity. Pulmonary hypertension defined as PASP greater than 35 mmHg or TR velocity greater than 2.8 m/s. Prevalence will be calculated.

  Baseline

Secondary Outcomes (4)

• Prevalence of right ventricular dysfunction

  Baseline

• Pulmonary artery systolic pressure

  Baseline

• Tricuspid annular plane systolic excursion (TAPSE)

  Baseline

• Right ventricular fractional area change

  Baseline

Study Arms (1)

Single cohort: Patients with myeloproliferative neoplasms

Adult patients with myeloproliferative neoplasms who will undergo clinical, laboratory, and echocardiographic assessment for pulmonary hypertension and right ventricular dysfunction.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with confirmed myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, or primary myelofibrosis) attending the Hematology Unit and Critical Care Department at Assiut University Hospital.

You may qualify if:

• \- Age 18 years or older
• Confirmed diagnosis of myeloproliferative neoplasm (polycythemia vera, essential thrombocythemia, or primary myelofibrosis)
• Stable clinical condition
• Written informed consent

You may not qualify if:

• \- Significant left-sided valvular heart disease
• Congenital heart disease
• COPD or interstitial lung disease causing pulmonary hypertension
• Poor echocardiographic window

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Myeloproliferative Disorders; Ventricular Dysfunction, Right; Hypertension, Pulmonary

Condition Hierarchy (Ancestors)

Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases; Ventricular Dysfunction; Heart Diseases; Cardiovascular Diseases; Lung Diseases; Respiratory Tract Diseases; Hypertension; Vascular Diseases

Study Officials

• Refaat f abdel all, prof

  Critical care unit Internal Medicine Department, Assiut University Hospitals

  STUDY CHAIR

Central Study Contacts

Esraa M Ahmed, Resident

CONTACT

+20 10 99071931; esraamedhat449@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident Physician

Study Record Dates

• First Submitted: September 17, 2026
• First Posted: September 22, 2026
• Study Start: September 20, 2026
• Primary Completion (Estimated): September 20, 2027
• Study Completion (Estimated): March 10, 2028
• Last Updated: September 22, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share